keyword
MENU ▼
Read by QxMD icon Read
search

Etanercept

keyword
https://www.readbyqxmd.com/read/29680792/-pneumocystis-jiroveci-pneumonia-in-a-patient-taking-benepali-for-rheumatoid-arthritis
#1
Kay Frances Graham, Anne McEntegart
We present a case of a 57-year-old woman who contracted Pneumocystis jiroveci pneumonia while on Benepali, the biosimilar version of etanercept for rheumatoid arthritis. She had seropositive erosive disease. She was admitted to clinic with a 2-week history of dyspnoea, dry cough and fever. Her initial examination showed her to be hypoxic on air with saturations of 77% and left basal crackles. Her admission chest X-ray showed fine reticular shadowing, with an initial suspicion of pulmonary fibrosis. She was empirically treated for community-acquired pneumonia but continued to deteriorate with a worsening type 1 respiratory failure...
April 21, 2018: BMJ Case Reports
https://www.readbyqxmd.com/read/29676408/response-to-comment-on-new-alternatives-for-autoimmune-disease-treatments-physicochemical-and-clinical-comparability-of-biosimilar-etanercept
#2
COMMENT
Mariana P Miranda-Hernández, Carlos A López-Morales, Francisco C Perdomo-Abúndez, Rodolfo D Salazar-Flores, Nancy D Ramírez-Ibanez, Nestor O Pérez, Aaron Molina-Pérez, Jorge Revilla-Beltri, Emilio Medina-Rivero, Luis F Flores-Ortiz
No abstract text is available yet for this article.
2018: Journal of Immunology Research
https://www.readbyqxmd.com/read/29671665/effects-of-etanercept-on-the-patient-perceived-results-pros-in-patients-with-moderate-to-severe-plaque-psoriasis-systematic-review-of-the-literature-and-meta-analysis
#3
Jose Manuel Carrascosa, Francisco Rebollo, Susana Gómez, Pablo de la Cueva
PURPOSE: To evaluate the efficacy of etanercept (ETN) compared with placebo for moderate-to-severe psoriasis regarding patients reported outcomes (PROs). METHODS: Systematic review of studies retrieved by a sensitive search strategy in Medline, Embase, Cochrane Library. SELECTION CRITERIA: (population) studies had to include patients with for moderate-to-severe psoriasis; (intervention and control) studies had to test ETN vs placebo; and (outcomes), studies had to report PROs including quality of life, pain, pruritus or sleep...
April 19, 2018: Journal of Dermatological Treatment
https://www.readbyqxmd.com/read/29671370/synovial-inflammation-analyzed-by-3-t-magnetic-resonance-imaging-in-etanercept-treated-patients-with-rheumatoid-arthritis-indicates-persistent-disease-activity-despite-of-clinical-remission-a-pilot-study
#4
Mara Oleszowsky, Winfried Willinek, Milka Marinova, Matthias F Seidel
OBJECTIVES: To evaluate joint inflammation using 3-T MRI in rheumatoid arthritis (RA) patients treated with conventional disease modifying anti-rheumatic drugs (cDMARDs) as compared to inhibitors for tumor necrosis factor α (TNFi) over 12 months. METHODS: Prospective epidemiologic clinical pilot study using the RA MRI system (RAMRIS), the visual analog scale (VAS, 0-100) and the Disease Activity Score 28-joint count (DAS28) at baseline, four and 12 months after initiation of etanercept (ETA)...
April 19, 2018: Modern Rheumatology
https://www.readbyqxmd.com/read/29670468/analysis-of-drug-effects-on-primary-human-coronary-artery-endothelial-cells-activated-by-serum-amyloid-a
#5
K Lakota, D Hrušovar, M Ogrič, K Mrak-Poljšak, S Čučnik, M Tomšič, B Božič, P Žigon, S Sodin-Semrl
Background: RA patients have a higher incidence of cardiovascular diseases compared to the general population. Serum amyloid A (SAA) is an acute-phase protein, upregulated in sera of RA patients. Aim: To determine the effects of medications on SAA-stimulated human coronary artery endothelial cells (HCAEC). Methods: HCAEC were preincubated for 2 h with medications from sterile ampules (dexamethasone, methotrexate, certolizumab pegol, and etanercept), dissolved in medium (captopril) or DMSO (etoricoxib, rosiglitazone, meloxicam, fluvastatin, and diclofenac)...
2018: Mediators of Inflammation
https://www.readbyqxmd.com/read/29669173/second-generation-syk-inhibitor-entospletinib-ameliorates-fully-established-inflammation-and-bone-destruction-in-the-cherubism-mouse-model
#6
Tetsuya Yoshimoto, Tatsuhide Hayashi, Toshio Kondo, Mizuho Kittaka, Ernst J Reichenberger, Yasuyoshi Ueki
Cherubism is a craniofacial disorder characterized by maxillary and mandibular bone destruction. Gain-of-function mutations in the SH3-domain binding protein 2 (SH3BP2) are responsible for the excessive bone resorption caused by fibrous inflammatory lesions. A homozygous knock-in (KI) mouse model for cherubism (Sh3bp2KI/KI ) develops autoinflammation resulting in systemic bone destruction. While administration of the TNF-α blocker etanercept to neonatal Sh3bp2KI/KI mice prevented the disease onset, this therapy was not effective for adult Sh3bp2KI/KI mice or human cherubism patients who already had lesions...
April 18, 2018: Journal of Bone and Mineral Research: the Official Journal of the American Society for Bone and Mineral Research
https://www.readbyqxmd.com/read/29668637/successful-mesenchymal-stem-cell-treatment-of-leg-ulcers-complicated-by-behcet-disease-a-case-report-and-literature-review
#7
Yanhong Li, Zhongming Wang, Yi Zhao, Yubin Luo, Wangdong Xu, Tony N Marion, Yi Liu
RATIONALE: Behçet disease (BD) is a recurrent vasculitis characterized by oral and genital mucous membrane ulcers, uveitis, and skin lesions but only rarely leg ulcers. To our knowledge, no efficacious therapy has been described for BD patients with complicating, destructive leg ulcers. PATIENT CONCERNS: Here, We report the case of a 55-year-old woman with generalized erythema nodosum-like, papulopustular lesions, recurrent oral and genital ulcers accompanied with recurrent leg ulcers and trouble walking...
April 2018: Medicine (Baltimore)
https://www.readbyqxmd.com/read/29667324/estimation-of-cost-savings-between-2011-and-2014-attributed-to-infliximab-biosimilar-in-the-south-korean-healthcare-market-real-world-evidence-using-a-nationwide-database
#8
Jiyoun Kim, Dongmun Ha, Inmyung Song, Haesun Park, Sang-Won Lee, Eui-Kyung Lee, Ju-Young Shin
AIM: The introduction of biosimilars is expected to reduce the cost of biologic drugs, but the actual cost savings have not yet been quantified in Korea. The aim of this study was to estimate the annual cost savings attributed to the introduction of infliximab biosimilar. METHODS: We conducted a retrospective analysis using data from the Health Insurance Review and Assessment Service-National Patients Sample (HIRA-NPS) between 2011 and 2014. The study subjects were patients who were treated with infliximab, adalimumab or etanercept...
April 17, 2018: International Journal of Rheumatic Diseases
https://www.readbyqxmd.com/read/29667098/treatment-patterns-among-patients-with-rheumatic-disease-rheumatoid-arthritis-ra-ankylosing-spondylitis-as-psoriatic-arthritis-psa-and-undifferentiated-arthritis-una-treated-with-subcutaneous-tnf-inhibitors
#9
Kathleen Tymms, Geoff Littlejohn, Hedley Griffiths, Julien de Jager, Paul Bird, Fred Joshua, Peter Nash, Malcolm Handel, Hamish McManus, Belinda E Butcher, Peter Youssef
The aim was to describe the real-world treatment persistence of subcutaneous TNF inhibitors (TNFi) for patients with inflammatory rheumatic disease newly initiating treatment with biologic disease-modifying antirheumatic drugs (bDMARD). This was a retrospective cohort study that extracted data for new users of TNFi between 1 August 2010 and 31 August 2016 from the Australian Optimising Patient outcome in Australian RheumatoLogy (OPAL) registry. Patients were 1:1 propensity-score matched with golimumab based on their age, sex, year of index, C-reactive protein level, baseline treatment combination and disease...
April 18, 2018: Clinical Rheumatology
https://www.readbyqxmd.com/read/29661292/etanercept-restores-vasocontractile-sensitivity-affected-by-mesenteric-ischemia-reperfusion
#10
S Erpulat Ozis, Tamila Akhayeva, Sahika Guner, Sibel S Kilicoglu, Arzu Pampal
BACKGROUND: The aim of the study is to evaluate in vivo and in vitro effects of etanercept, a soluble tumor necrosis factor receptor, on the contractile responses of superior mesenteric artery in an experimental mesenteric ischemia and reperfusion model. MATERIAL AND METHODS: After obtaining animal ethics committee approval, 24 Sprague-Dawley rats were allocated to three groups. Control group (Gr C, n = 6) underwent a sham operation, whereas ischemia/reperfusion and treatment groups underwent 90 min ischemia and 24-h reperfusion (Gr I/R, n = 12; Gr I/R+E, n = 6)...
June 2018: Journal of Surgical Research
https://www.readbyqxmd.com/read/29660425/certolizumab-pegol-for-the-treatment-of-chronic-plaque-psoriasis-results-through-48-weeks-of-a-phase-3-multicenter-randomized-double-blinded-etanercept-and-placebo-controlled-study-cimpact
#11
Mark Lebwohl, Andrew Blauvelt, Carle Paul, Howard Sofen, Jolanta Węgłowska, Vincent Piguet, Daniel Burge, Robert Rolleri, Janice Drew, Luke Peterson, Matthias Augustin
BACKGROUND: Phase 2 psoriasis studies with the Fc-free, PEGylated, anti-tumor necrosis factor biologic certolizumab pegol demonstrated meaningful clinical activity. OBJECTIVE: Assess safety and efficacy of certolizumab in adults with moderate-to-severe chronic plaque psoriasis. METHODS: Patients were randomized 3:3:1:3 to certolizumab 400 mg, 200 mg, or placebo every 2 weeks for 16 weeks or etanercept 50 mg twice-weekly for 12 weeks. Certolizumab-treated patients achieving ≥75% reduction in psoriasis area and severity index at Week 16 were re-randomized to certolizumab or placebo for 32 weeks...
April 13, 2018: Journal of the American Academy of Dermatology
https://www.readbyqxmd.com/read/29657832/predictive-value-of-serum-calprotectin-s100a8-a9-for-clinical-response-after-starting-or-tapering-anti-tnf-treatment-in-patients-with-rheumatoid-arthritis
#12
Lieke Tweehuysen, Nathan den Broeder, Noortje van Herwaarden, Leo A B Joosten, Peter L van Lent, Thomas Vogl, Frank H J van den Hoogen, Rogier M Thurlings, Alfons A den Broeder
Objectives: Calprotectin (S100A8/A9) has been correlated with disease activity in rheumatoid arthritis (RA). The aim of this study was to investigate the predictive value of serum calprotectin for clinical response after starting and tapering anti-tumour necrosis factor treatment in RA. Methods: Serum samples and clinical outcomes were derived from two longitudinal RA studies.At baseline (starting or tapering of adalimumab or etanercept), calprotectin levels were determined by ELISA...
2018: RMD Open
https://www.readbyqxmd.com/read/29652659/efficiency-of-dose-reduction-strategy-of-etanercept-in-patients-with-axial-spondyloarthritis
#13
Fan Lian, Jun Zhou, Yu Wang, Dongying Chen, Hanshi Xu, Liuqin Liang
OBJECTIVES: To evaluate the efficacy of different tapering or discontinuation strategies of etanercept in a cohort of axial spondyloarthritis from South China. METHODS: We performed a retrospective cohort study. Axial SpA patients who achieved clinical remission for at least 6 months after receiving a standard dose of etanercept therapy were enrolled. Different tapering or discontinuation strategies were compared. RESULTS: Altogether, 258 cases were enrolled...
April 13, 2018: Clinical and Experimental Rheumatology
https://www.readbyqxmd.com/read/29651442/comment-on-new-alternatives-for-autoimmune-disease-treatments-physicochemical-and-clinical-comparability-of-biosimilar-etanercept
#14
COMMENT
Brian Hassett, Steven Vicik, Brian Fitzpatrick
No abstract text is available yet for this article.
2018: Journal of Immunology Research
https://www.readbyqxmd.com/read/29624580/estimating-the-response-and-economic-burden-of-rheumatoid-arthritis-patients-treated-with-biologic-disease-modifying-antirheumatic-drugs-in-taiwan-using-the-national-health-insurance-research-database-nhird
#15
Qiang Shi, Ko-Jen Li, Tamas Treuer, Bruce C M Wang, Carol L Gaich, Chien-Hsun Lee, Wen-Shuo Wu, Wesley Furnback, Chao-Hsiun Tang
BACKGROUND: Previous studies in Taiwan utilizing the Taiwan's National Health Insurance Database (NHIRD) have estimated the direct healthcare costs of RA patients, but they have not focused on patients on bDMARDs, or considered patients' response to therapy. OBJECTIVES: The objective of this study was to estimate the rate of inadequate response for patients newly treated with biologic disease-modifying antirheumatic drugs (bDMARDs) as well as their costs and resource use...
2018: PloS One
https://www.readbyqxmd.com/read/29622483/mesenchymal-stromal-cell-exosome-enhanced-regulatory-t-cell-production-through-an-antigen-presenting-cell-mediated-pathway
#16
Bin Zhang, Ronne Wee Yeh Yeo, Ruenn Chai Lai, Eugene Wei Kian Sim, Keh Chuang Chin, Sai Kiang Lim
BACKGROUND AIMS: The immunomodulatory property of mesenchymal stromal cell (MSC) exosomes is well documented. On the basis of our previous report that MSC exosomes increased regulatory T-cell (Treg) production in mice with allogenic skin graft but not in ungrafted mice, we hypothesize that an activated immune system is key to exosome-mediated Treg production. METHODS: To test our hypothesis, MSC exosomes were incubated with mouse spleen CD4+ T cells that were activated with either anti-CD3/CD28 mAbs or allogenic antigen-presenting cell (APC)-enriched spleen CD11c+ cells to determine whether production of mouse CD4+ CD25+ T cells or CD4+ CD25+ Foxp3+ Tregs could be induced...
April 2, 2018: Cytotherapy
https://www.readbyqxmd.com/read/29619911/early-use-of-etanercept-for-graft-versus-host-disease-after-liver-transplant-the-importance-of-broad-spectrum-infective-prophylaxis
#17
Annalisa Boscolo, Eugenia Menin, Beatrice Zelaschi, Laura Albertoni, Giacomo Zanus, Fabio Baratto
Graft-versus-host-disease after orthotopic liver transplant is a rare and life-threatening complication. The diagnosis is challenging and usually confirmed by chimerism and skin biopsies. The most common cause of death is sepsis (60%), and broad-spectrum antibiotics and antifungal prophylaxis are strongly recommended. We present a case of a 61-year-old man with hepatocellular carcinoma and a previous history of metabolic and alcoholic cirrhosis who underwent orthotopic liver transplant. The immunosuppression regimen consisted of corticosteroids, calcineurin inhibitor, and mammalian target of rapamycin complex 1 inhibitor...
April 4, 2018: Experimental and Clinical Transplantation
https://www.readbyqxmd.com/read/29619856/number-needed-to-treat-and-costs-per-responder-among-biologic-treatments-for-moderate-to-severe-psoriasis-a-network-meta-analysis
#18
April W Armstrong, Keith A Betts, James E Signorovitch, Murali Sundaram, Junlong Li, Arijit X Ganguli, Eric Q Wu
BACKGROUND: The clinical benefits of biologic therapies for moderate-to-severe psoriasis are well established, but wide variations exist in patient response. OBJECTIVES: To determine the number needed to treat (NNT) to achieve a 75% and 90% reduction in the Psoriasis Area and Severity Index (PASI-75/90) with FDA-approved agents and evaluate the incremental cost per PASI-75 or PASI-90 responder. METHODS: The relative probabilities of achieving PASI-75 and PASI-90, as well as NNTs were estimated using a network meta-analysis...
April 5, 2018: Current Medical Research and Opinion
https://www.readbyqxmd.com/read/29619032/an-autocrine-tnf%C3%AE-tumor-necrosis-factor-receptor-2-loop-promotes-epigenetic-effects-inducing-human-treg-stability-in-vitro
#19
Paulo C M Urbano, Hans J P M Koenen, Irma Joosten, Xuehui He
A crucial issue for Treg-based immunotherapy is to maintain a bona fide Treg phenotype as well as suppressive function during and after ex vivo expansion. Several strategies have been applied to harness Treg lineage stability. For instance, CD28 superagonist stimulation in vitro , in the absence of CD3 ligation, is more efficient in promoting Treg proliferation, and prevention of pro-inflammatory cytokine expression, such as IL-17, as compared to CD3/CD28-stimulated Treg. Addition of the mTOR inhibitor rapamycin to Treg cultures enhances FOXP3 expression and Treg stability, but does impair proliferative capacity...
2018: Frontiers in Immunology
https://www.readbyqxmd.com/read/29618976/the-efficacy-and-safety-of-mainstream-medications-for-patients-with-cdmard-na%C3%A3-ve-rheumatoid-arthritis-a-network-meta-analysis
#20
Weiyan Cai, Youyi Gu, Huanqin Cui, Yinyin Cao, Xiaoliang Wang, Yi Yao, Mingyu Wang
Background: The mainstream medications for rheumatoid arthritis (RA) include conventional disease-modifying antirheumatic drugs (cDMARDs), which mostly are methotrexate (MTX), and biologic agents such as adalimumab (ADA), certolizumab (CZP), etanercept (ETN), golimumab (GOL), infliximab (IFX), and tocilizumab (TCZ). This network meta-analysis was aimed at evaluating the efficacy and safety of the medications above and interventions combining cDMARDs and biologic agents for patients with RA. Methods: PubMed, EMBASE, Cochrane Library, and ClinicalTrials...
2018: Frontiers in Pharmacology
keyword
keyword
26126
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"